Recruiting NCT04924998
Clinical Study for AL-CM
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: current treatment of AL-CM.
- Who it may be relevant to
- Registry conditions: Immunoglobulin Light Amyloidosis Cardiomyopathy. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Study Protocol for the Treatment of Immunoglobulin Light Chain Amyloidosis Cardiomyopathy
Overview
In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.
Interventions
- Drug current treatment of AL-CM
current treatment of AL-CM
Primary outcome measures
- Primary Outcome [Time frame: 10 year]
Eligibility criteria
Inclusion criteria
- Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine;
- Patients have the ability to understand the test, can cooperate with investigators.
Exclusion criteria
- Unable to understand or unwilling to fill in informed consent forms or follow visitors
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China — Hangzhou
Identifiers
NCT: NCT04924998 · 2021-0133